Limits...
Molecular classification and prediction in gastric cancer.

Lin X, Zhao Y, Song WM, Zhang B - Comput Struct Biotechnol J (2015)

Bottom Line: Unprecedented whole-genome-scale data have been catalyzing and advancing the molecular subtyping approach.We identified the consensus patterns across these signatures and identified the underlying molecular pathways and biological functions.The identification of molecular subtyping of gastric adenocarcinoma and the development of integrated genomics approaches for clinical applications such as prediction of clinical intervening emerge as an essential phase toward personalized medicine in treating gastric cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, NY 10029, USA ; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fujian Provincial Cancer Hospital, No. 420 Fuma Road, Jinan District, Fuzhou, Fujian 350014, PR China.

ABSTRACT
Gastric cancer, a highly heterogeneous disease, is the second leading cause of cancer death and the fourth most common cancer globally, with East Asia accounting for more than half of cases annually. Alongside TNM staging, gastric cancer clinic has two well-recognized classification systems, the Lauren classification that subdivides gastric adenocarcinoma into intestinal and diffuse types and the alternative World Health Organization system that divides gastric cancer into papillary, tubular, mucinous (colloid), and poorly cohesive carcinomas. Both classification systems enable a better understanding of the histogenesis and the biology of gastric cancer yet have a limited clinical utility in guiding patient therapy due to the molecular heterogeneity of gastric cancer. Unprecedented whole-genome-scale data have been catalyzing and advancing the molecular subtyping approach. Here we cataloged and compared those published gene expression profiling signatures in gastric cancer. We summarized recent integrated genomic characterization of gastric cancer based on additional data of somatic mutation, chromosomal instability, EBV virus infection, and DNA methylation. We identified the consensus patterns across these signatures and identified the underlying molecular pathways and biological functions. The identification of molecular subtyping of gastric adenocarcinoma and the development of integrated genomics approaches for clinical applications such as prediction of clinical intervening emerge as an essential phase toward personalized medicine in treating gastric cancer.

No MeSH data available.


Related in: MedlinePlus

Applications of molecular profiling in diagnosis and treatment of GC. The applications of gene expression profiling in GC include diagnosis, subgroup, TNM staging, treatment, and prognosis evaluation. EGC: early gastric cancer; CUP: cancer of unknown primary site.
© Copyright Policy - CC BY
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556804&req=5

f0005: Applications of molecular profiling in diagnosis and treatment of GC. The applications of gene expression profiling in GC include diagnosis, subgroup, TNM staging, treatment, and prognosis evaluation. EGC: early gastric cancer; CUP: cancer of unknown primary site.

Mentions: Here we cataloged and compared published gene expression profiling signatures in GC as well as more integrated genomic features of GC from gene expression, somatic mutation, chromosomal instability, Epstein–Bar Virus (EBV) virus infection, and DNA methylation. We highlighted the consensus patterns across these signatures, identified their associated molecular pathways, and underscored their prediction power of GC stratification and chemotherapy sensitivity. Fig. 1 outlines the contents of this review which focuses on applications of gene expression profiling in diagnosis, prognosis, and therapeutic intervention of GC.


Molecular classification and prediction in gastric cancer.

Lin X, Zhao Y, Song WM, Zhang B - Comput Struct Biotechnol J (2015)

Applications of molecular profiling in diagnosis and treatment of GC. The applications of gene expression profiling in GC include diagnosis, subgroup, TNM staging, treatment, and prognosis evaluation. EGC: early gastric cancer; CUP: cancer of unknown primary site.
© Copyright Policy - CC BY
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556804&req=5

f0005: Applications of molecular profiling in diagnosis and treatment of GC. The applications of gene expression profiling in GC include diagnosis, subgroup, TNM staging, treatment, and prognosis evaluation. EGC: early gastric cancer; CUP: cancer of unknown primary site.
Mentions: Here we cataloged and compared published gene expression profiling signatures in GC as well as more integrated genomic features of GC from gene expression, somatic mutation, chromosomal instability, Epstein–Bar Virus (EBV) virus infection, and DNA methylation. We highlighted the consensus patterns across these signatures, identified their associated molecular pathways, and underscored their prediction power of GC stratification and chemotherapy sensitivity. Fig. 1 outlines the contents of this review which focuses on applications of gene expression profiling in diagnosis, prognosis, and therapeutic intervention of GC.

Bottom Line: Unprecedented whole-genome-scale data have been catalyzing and advancing the molecular subtyping approach.We identified the consensus patterns across these signatures and identified the underlying molecular pathways and biological functions.The identification of molecular subtyping of gastric adenocarcinoma and the development of integrated genomics approaches for clinical applications such as prediction of clinical intervening emerge as an essential phase toward personalized medicine in treating gastric cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, NY 10029, USA ; Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fujian Provincial Cancer Hospital, No. 420 Fuma Road, Jinan District, Fuzhou, Fujian 350014, PR China.

ABSTRACT
Gastric cancer, a highly heterogeneous disease, is the second leading cause of cancer death and the fourth most common cancer globally, with East Asia accounting for more than half of cases annually. Alongside TNM staging, gastric cancer clinic has two well-recognized classification systems, the Lauren classification that subdivides gastric adenocarcinoma into intestinal and diffuse types and the alternative World Health Organization system that divides gastric cancer into papillary, tubular, mucinous (colloid), and poorly cohesive carcinomas. Both classification systems enable a better understanding of the histogenesis and the biology of gastric cancer yet have a limited clinical utility in guiding patient therapy due to the molecular heterogeneity of gastric cancer. Unprecedented whole-genome-scale data have been catalyzing and advancing the molecular subtyping approach. Here we cataloged and compared those published gene expression profiling signatures in gastric cancer. We summarized recent integrated genomic characterization of gastric cancer based on additional data of somatic mutation, chromosomal instability, EBV virus infection, and DNA methylation. We identified the consensus patterns across these signatures and identified the underlying molecular pathways and biological functions. The identification of molecular subtyping of gastric adenocarcinoma and the development of integrated genomics approaches for clinical applications such as prediction of clinical intervening emerge as an essential phase toward personalized medicine in treating gastric cancer.

No MeSH data available.


Related in: MedlinePlus